✍🏼 Fangming Wang, Liyuan Wu, Le Yin, Hui Shi, Yuchun Gu, Nianzeng Xing

🏠 Chinese Academy of Medical Sciences and Peking Union Medical College, China

📑 Clinical and Translation Medicine (2022) – Read the Article

Abstract
The chimeric antigen receptor NK-92 (CAR NK-92) cell targeting the prostate-specific membrane antigen (PSMA) has shown antitumour effects in castration-resistant prostate cancer (CRPC). However, the expression changes of programmed death ligand 1 (PD-L1) and its mechanisms on CAR NK-92 and CRPC cells and the effect of the anti-PD-L1 monoclonal antibody (mAb) on PD-L1 expressed on CAR NK-92 cells remain unknown.